
|Articles|October 1, 2003
New Products & Services
Once-daily quinolone gains new urology indications: West Haven, CT-Bayer Pharmaceuticals has received FDA approval to market its once-daily, extended-release fluoroquinolone, ciprofloxacin (Cipro XR), for two new indications: complicated urinary tract infections and acute uncomplicated pyelonephritis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











